[1] EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol, 2015,63:199-236.
[2] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016,63:261-283.
[3] Lonardo A, Byrne CD, Caldwell SH, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,64:1388-1389.
[4] Paranaguá-Vezozzo DC, Andrade A, Mazo DF, et al. Concordance of non-invasive mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis C. World J Hepatol, 2017,9:436-442.
[5] Zhu MY, Zou X, Li Q, et al. A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection. J Viral Hepat, 2017,24:589-598.
[6] Leroy V, Sturm N, Faure P, et al. Prospective evaluation of FibroTest, FibroMeter, and HepaScore for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol, 2014,61:28-34.
[7] Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol, 2016,64:773-780.
[8] Ahmed HE, Sharaf EAEA, Ahmed SZE, et al. VAP score as a novel non-invasive liver fibrosis model in patients with chronic hepatitis C. Hepatol Res, 2017.
[9] Yamazaki T, Joshita S, Umemura T, et al. Association of serum autotaxin levels with liver fibrosis in patients with chronic hepatitis C. Sci Rep, 2017,7:46705.
[10] Shaker OG, Senousy MA. Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients. J Viral Hepat, 2017,24:636-644.
[11] Toson EA, Shiha GE, El-Mezayen HA, et al. Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link. Eur J Gastroenterol Hepatol, 2017,29:199-207.
[12] Shiha G, Seif S, Eldesoky A, et al. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int, 2017,11:286-291.
[13] Yu F, Zhou G, Huang K, et al. Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients. J Viral Hepat, 2017,24:580-588.
[14] 杨晴, 刘东屏, 李鲁平, 等. 慢性乙型肝炎肝纤维化非创伤性诊断模型的建立与评价. 中华肝脏病杂志, 2017,25:15-20.
[15] Zachou K, Gabeta S, Shums Z, et al. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. Eur J Intern Med, 2017,38:83-88.
[16] Gaia S, Campion D, Evangelista A, et al. Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data. Liver Int, 2015,35:2027-2035.
[17] 欧晓娟, 王晓明, 吴晓宁, 等. FibroTouch与FibroScan在慢性乙型肝炎患者肝纤维化评估中的比较. 中华肝脏病杂志, 2015,23:103-106.
[18] Zhao J, Zhai F, Cheng J, et al. Evaluating the significance of viscoelasticity in diagnosing early-stage liver fibrosis with transient elastography. PLoS One, 2017,12:e0170073.
[19] Herrmann E, de Lédinghen V, Cassinotto C, et al. Assessment of biopsy-proven liver fibrosis by two-climen sional shear wave elastography: An individual patient data based meta-analysis. Hepatology, 2017.
[20] Moustafa EF, Makhlouf N, Hassany SM, et al. Non-invasive assessment of liver fibrosis in patients with hepatitis C: Shear wave elastography and colour Doppler velocity profile technique versus liver biopsy. Arab J Gastroenterol, 2017,18:6-12.
[21] Bertrais S, Boursier J, Ducancelle A, et al. Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests. J Gastroenterol Hepatol, 2016.
[22] Wang J, Malik N, Yin M, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. World J Gastroenterol, 2017,23:859-868.
[23] Shi HL, Liu LN, Shao M. Letter: comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for noninvasive diagnosis of advanced fibrosis in biopsy-proven NAFLD. Aliment Pharmacol Ther, 2017,45:478-479.
[24] Cui J, Heba E, Hernandez C, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology, 2016,63:453-461.
[25] Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology, 2017,152:598-607.e2.
[26] Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology, 2016,150:626-637.e7.
[27] Loomba R, Cui J, Wolfson T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol, 2016,111:986-994.
[28] Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005,128:343-350.
[29] Liang XE, Dai L, Yang SL, et al. Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection. Dig Liver Dis, 2016,48:512-518.
[30] Chen X, Wen H, Zhang X, et al. Development of a simple noninvasive model to predict significant fibrosis in patients with chronic hepatitis B: combination of ultrasound elastography, serum biomarkers, and individual characteristics. Clin Transl Gastroenterol, 2017,8:e84.
[31] Afyon M. Could viral load combined with indirect serum markers be an option for predicting the degree of liver fibrosis in treatment-naive chronic hepatitis B patients. Rev Esp Enferm Dig, 2017,109:166-167.
[32] Voican CS, Louvet A, Trabut JB, et al. Transient elastography alone and in combination with FibroTest(○R) for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int, 2017, 37: 1697-1705.
[33] Liang XE, Zhong C, Huang L, et al. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers. J Gastroenterol Hepatol, 2017,32:459-465.
[34] Chen YP, Hu XM, Liang XE, et al. Stepwise application of FIB-4, red cell distribution width-platelet ratio and APRI for compensated hepatitis B fibrosis detection. J Gastroenterol Hepatol, 2017.
[35] Boursier J, de Ledinghen V, Leroy V, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol, 2017,66:1158-1165. |
